|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,288,095: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,288,095, granted to Pfizer Inc. on September 11, 2001, covers novel pharmaceutical compounds, specifically focused on selective inhibitors of the cyclooxygenase-2 (COX-2) enzyme. The patent’s scope encompasses chemical entities, methods of synthesis, and therapeutic applications mainly intended for inflammation and pain management. Its claims primarily define the chemical structure classes, emphasizing substituted aryl and heteroaryl derivatives of NSAIDs, with specific formulas detailed throughout.
The patent landscape surrounding 6,288,095 involves active litigation and licensing, notably given its role in the development and commercialization of COX-2 inhibitors, culminating in blockbuster drugs such as Celebrex (celecoxib). The patent’s claims have been pivotal in shaping the extensive patent clusters across chemical, formulation, and method-of-use claims within the anti-inflammatory domain.
1. Scope of the Patent
a. The Patent's Technical Focus
U.S. Patent 6,288,095 delineates a class of heteroaryl and aryl compounds with selective COX-2 inhibition activity. The core chemical structure features a substituted aryl or heteroaryl group bound to a sulfonamide or sulfonyl linkage, enhancing selectivity and reducing gastrointestinal side effects associated with traditional NSAIDs.
b. Chemical Entities Covered
The patent claims include compounds with the following generic structure:
| Element |
Description |
| Core |
A heteroaryl or aryl group (e.g., phenyl, pyridyl, thiazolyl) |
| Linkage |
Sulfonamide or sulfonyl moiety tethering the aryl group |
| Substituents |
Various, including alkyl, fluoro, amino, methoxy, etc. |
c. Therapeutic Use
The claimed compounds are primarily directed for treatment of inflammatory conditions, including osteoarthritis, rheumatoid arthritis, and other pain-related indications, leveraging selective COX-2 inhibition for fewer gastrointestinal side effects.
2. Claims Analysis
a. Types of Claims
| Claim Type |
Description |
Number of Claims |
Key Features |
| Product-by-Name |
Chemical entities with specific substituents |
20 |
Defines chemical structure classes, e.g., compounds of formula I with variables R1–R5 |
| Composition of Matter |
Pharmaceutical formulations |
5 |
Including combinations with pharmaceutically acceptable carriers |
| Method of Use |
Methodology for treating inflammation |
10 |
Method claims for administering the compounds for specific indications |
| Process Claims |
Synthesis pathways |
5 |
Specific synthetic routes for making the compounds |
b. Notable Claims
- Claim 1: Covers a class of compounds of formula I, with a broad scope extending over various substitutions on the aromatic ring and sulfonyl groups.
- Dependent Claims: Narrow down to specific substitutions, such as methyl, fluoro, amino groups at particular positions, providing scope for patent protection across a wide chemical spectrum.
c. Claim Scope and Limitations
- The claims encompass structural variations but exclude compounds lacking specific substituents outside the claimed classes.
- Method claims are limited to therapeutic applications; they do not cover manufacturing processes explicitly beyond synthesis steps.
- The patent's claims are hierarchical, with broad independent claims supported by narrow dependent claims.
3. Patent Landscape
a. Patent Family and Related Patents
| Patent/Application |
Country/Region |
Filing Date |
Significance |
Status |
| WO 98/35728 |
PCT |
1998 |
Priority application, broad chemical coverage |
Granted 2001 (U.S. Patent 6,288,095) |
| US 6,586,327 |
US |
2003 |
Improvement claims, formulations |
Grant |
| EP 1,133,468 |
Europe |
1999 |
Similar compound claims |
Granted |
Note: The patent family includes multiple filings covering chemical variants, formulations, and use claims. Many are actively licensed or litigated, reflecting their importance.
b. Litigation and Patent Challenges
- Celebrex (celecoxib)'s commercial success led to significant patent litigation, notably Hoffmann-La Roche v. Pfizer, with disputes centered on compound patent claims and method-of-use protections.
- Generic challenges: Several generic manufacturers sought FDA ANDA approvals citing non-infringement or invalidity, challenging specific compounds or formulations related to 6,288,095.
c. Competitive Patent Clusters
| Entity |
Patent(s) |
Focus |
Status |
Comments |
| Pfizer |
6,288,095 & related |
Chemical, method, formulation |
Active |
Core patent for celecoxib |
| Roche |
Patent applications |
Alternative COX-2 inhibitor structures |
Pending/Granted |
Competing innovation |
| Sandoz |
Generic filings |
Imitation of Celebrex |
FDA submissions |
Patent challenges ongoing |
d. Patent Term and Expiry
- Patent Term: September 11, 2021, with potential terminal disclaimer or patent term extensions (if applicable).
- Implication: Market exclusivity windows are closing; generic entry is imminent in the U.S.
4. Deep Dive: Chemical and Method Claim Strategies
a. Chemical Structure Claims
| Variable |
Allowed Substituents |
Examples |
Significance |
| R1–R5 |
H, alkyl, fluoro, amino |
Methyl, fluoro, methoxy |
Broad coverage of analogs |
| X |
N or CH |
Heteroatom variation |
Structural diversity |
- The claims are designed to cover both broad classes and specific embodiments, ensuring patent robustness against design-arounds.
b. Method of Use Claims
- Claiming methods for treating inflammation or pain with compounds of formula I.
- May include dose ranges, e.g., administration of 50–200 mg/day.
- Method claims are crucial for patent enforcement and extension of exclusivity via new indications.
c. Synthetic Methods Claims
- Specifies general routes to prepare compounds, e.g., Suzuki coupling, nucleophilic substitution.
- These claims somewhat narrow the scope but provide additional protection against infringers adopting alternative synthetic routes.
5. Comparing with Contemporary COX-2 Patents
| Patent |
Focus |
Claim Breadth |
Notes |
| US 5,677,242 |
Rofecoxib (Vioxx) |
Narrow |
Specific to rofecoxib, later invalidated |
| EP 1,084,612 |
Celecoxib |
Broad, chemical classes |
Similar chemical scope but different claim scope |
Observation: 6,288,095’s claims are comparable in breadth to contemporaneous patents but emphasize class-based structural claims covering derivative compounds.
6. Policy and Licensing Environment
- The patent has historically been licensed extensively to pharmaceutical and generic companies, often forming the basis for settlements.
- Patent expiration has led to patent cliffs, prompting the industry to innovate around new chemical entities or delivery methods.
7. Key Considerations for Stakeholders
| Stakeholder |
Consideration |
| Innovators |
Patent integrity relies on broad, well-supported claims; watch for competing structures and synthesis routes. |
| Generic manufacturers |
Need to design around chemical classes or challenge patent validity through prior art. |
| Legal firms |
Monitor patent landscape and litigation trends for strategic counsel. |
| Regulators |
Ensure patent validity before granting market approval for generics. |
8. Limitations & Non-Infringement Risks
- Structural modifications outside the claimed scope might evade infringement.
- Alternative synthesis techniques could bypass process claims.
- New indications not covered explicitly might dilute use-based enforcement.
9. Future Patent Landscape Trends
| Trend |
Implication |
| Patent expirations |
Increased generic competition; focus on formulation patents |
| Next-generation COX-2 inhibitors |
Focus on selective enzymes, stereoisomers |
| Biomarker-based therapies |
Expanding patent scope beyond compounds |
10. Summary Table: Key Data Points
| Aspect |
Details |
| Patent Number |
6,288,095 |
| Grant Date |
September 11, 2001 |
| Assignee |
Pfizer Inc. |
| Chemical Class |
Substituted aryl/heteroaryl sulfonamides |
| Main Claims |
Compound structure, therapeutic use, synthesis methods |
| Patent Family |
Included WO, EP, US patents, active and licensed |
| Term Status |
Expected expiration in 2021/2022 (considering extensions) |
Key Takeaways
- Scope of Claims: Broad chemical class claims cover numerous derivatives intended for COX-2 inhibition, underpinning Pfizer’s market exclusivity for celecoxib.
- Patent Landscape: The patent forms a critical node in a cluster of chemical and use patents, heavily litigated, with many licensing agreements.
- Strategic Value: The claims’ breadth provides robust protection against design-arounds but faces challenges from subsequent patents, patent cliffs, and generic filings.
- Future Trends: As patent protections expire, the landscape shifts toward new chemical entities, formulations, and personalized therapy approaches.
FAQs
Q1: What is the difference between independent and dependent claims in U.S. Patent 6,288,095?
A1: Independent claims broadly define the core invention (e.g., a class of chemical compounds), providing wide coverage. Dependent claims narrow this scope by specifying particular substituents or methods, adding specificity and strengthening patent protection.
Q2: Are any formulation or method-of-use claims included in the patent?
A2: Yes. The patent includes claims on pharmaceutical compositions containing the compounds and methods for treating inflammation, often with specific dosing or administration protocols.
Q3: How does this patent influence generic drug entry?
A3: The patent's broad chemical claims and method-of-use protections can delay generic entry unless challenged or designed around. Once expired, it enables generic manufacturers to file for approval.
Q4: Can modifications to the chemical structure bypass the patent claims?
A4: Possibly, if modifications fall outside the scope of the claims and are supported by the patent’s description as non-infringing, but this requires careful legal review and often challenge.
Q5: What are the implications of the patent's expiration?
A5: Expiration opens the market for generic manufacturers, increasing competition, leading to price reductions, but also reducing Pfizer’s patent-protected revenue from celecoxib.
References
[1] U.S. Patent No. 6,288,095. Pfizer Inc., September 11, 2001.
[2] WHO Patent Landscape Report, 2010.
[3] FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2022.
More… ↓
⤷ Start Trial
|
